Miovisin (Acetylcholine Chloride)

Acetylcholine chloride acts as a direct cholinergic agonist, binding to muscarinic receptors on the iris sphincter muscle. This causes the muscle to contract, producing miosis, and also enhances outflow of aqueous humor through the trabecular meshwork, thereby reducing intraocular pressure.

The specific dose and administration schedule for Miovisin are determined by the prescribing ophthalmologist based on the patient’s condition, severity, and response to therapy. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Safety data for acetylcholine chloride in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by the treating physician.

To place an order, submit an enquiry on the Miovisin product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Miovisin belongs to the miotic class of drugs, which lower intraocular pressure by enhancing aqueous outflow and constricting the pupil. Unlike beta‑blockers or prostaglandin analogues that reduce production or increase outflow via different pathways, miotics act directly on muscarinic receptors, offering an alternative mechanism that may be preferred in certain clinical scenarios.

Miovisin should be stored at room temperature, below 25 °C, in its original packaging. Protect the container from direct light, moisture, and extreme temperature fluctuations to maintain product stability.

Miovisin is administered as an intraocular drop. The prescribed number of drops is placed directly onto the ocular surface, typically in the conjunctival sac, following the dosing schedule provided by the ophthalmologist.

Serious risks include acute angle‑closure glaucoma, severe ocular inflammation, systemic cholinergic effects such as bradycardia and hypotension, and allergic hypersensitivity reactions. Patients should be monitored closely for any signs of these events, and treatment should be discontinued if they occur.

Miovisin is contraindicated in patients with narrow‑angle or acute angle‑closure glaucoma, those with known hypersensitivity to acetylcholine chloride, and individuals taking systemic anticholinergic medications that could negate its effect. Physicians should evaluate each patient’s medical history before prescribing.